A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

NCT03747575 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: MSTT1041A
DRUG: Placebo

Sponsor

Genentech, Inc.